A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
- Disease/Condition
- Migraine
- Drug/Device/Intervention
- Rimegepant
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Phase
- N/A
- Start date
- Jan 19, 2024
- End date
- Jun 30, 2024
- Enrollment
- 120 participants
Treatment Satisfaction Questionnaire for Medication (TSQM),European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L),Headache Impact Test-6 (HIT-6),Work Productivity and Activity Impairment-General Health (WPAI-GH)
This study is a single-arm, prospective, multicenter, observational registry study. It plans
 to enroll 120 migraine patients who meet the inclusion criteria and are treated with
 rimegepant in selected hospital outpatient clinics in the Greater Bay Area. The main purpose
 of this study is to observe the effectiveness of rimegepant in treating migraines in a
 real-world clinical setting, including the impact of rimegepant on the quality of life,
 functioning, productivity status of migraine patients, and patients' satisfaction with the
 use of rimegepant in treating migraines.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06221267
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06221267 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and is currently Not yet recruiting. The study focuses on Migraine. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.